Pharming Group NV
AEX:PHARM
Intrinsic Value
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. [ Read More ]
The intrinsic value of one
PHARM
stock under the Base Case scenario is
1.11
EUR.
Compared to the current market price of 0.85 EUR,
Pharming Group NV
is
Undervalued by 23%.
Pharming Group NV's market capitalization is 570.4m EUR.
PHARM stock price is 0.85 EUR.
PHARM stock price (0.85 EUR) is 23% less than its Intrinsic Value (1.11 EUR).
PHARM stock price (0.85 EUR) is 45% less than its Relative Value (1.55 EUR). Open Relative Valuation
PHARM has upside potential of 118% compared to the average analyst price target.
Open Wall St Estimates
PHARM has negative Operating Income for the last twelve months.
PHARM's Revenue has been growing by 5% per year for the last 3 years.
PHARM has negative Net Income for the last twelve months.
PHARM's Revenue has grown by 19% over the past 12 months.
PHARM has positive three-year average ROE (Return on Equity): 15%. The company is efficient at transforming stockholders' equity into net income.
PHARM has negative Free Cash Flow for the last twelve months.
PHARM's Revenue is forecast to grow at a rate of 16% per year over the next 3 years.
PHARM's ROE (Return on Equity) for the past 12 months is negative and is equal to -5%.
PHARM has negative Net Debt. This means that the company has more cash and short-term investments (213m USD) than debt (166m USD).
PHARM's D/E (Debt to Equity) is very low and is equal to 0.76.
PHARM has positive three-year average ROIC (Return on Invested Capital): 20%. The company is efficient at using invested capital to generate operating income.
PHARM's ROE (Return on Equity) has significantly decreased in the last 3 years from 43% to -5%.
PHARM's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 67% to -11%.
PHARM's long-term assets (463m USD) exceed its long-term liabilties (244m USD).
PHARM's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -11%.
PHARM has positive Gross Profit for the last twelve months.
PHARM's Altman Z-Score is very low and is equal to 1.33.
PHARM's short-term assets (316m USD) exceed its short-term liabilties (78m USD).
PHARM doesn't generate enough operating income (-22m USD) to safely cover interest payments on its debt (4m USD).
Valuation Backtest
Pharming Group NV
Run backtest to discover the historical profit from buying and selling
PHARM
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Pharming Group NV
Balance Sheet Decomposition
Pharming Group NV
| Current Assets | 316.3m |
| Cash & Short-Term Investments | 213.4m |
| Receivables | 46.2m |
| Other Current Assets | 56.8m |
| Non-Current Assets | 146.5m |
| Long-Term Investments | 10.4m |
| PP&E | 33.5m |
| Intangibles | 71.3m |
| Other Non-Current Assets | 31.4m |
| Current Liabilities | 78m |
| Accounts Payable | 72.5m |
| Other Current Liabilities | 5.4m |
| Non-Current Liabilities | 166.1m |
| Long-Term Debt | 166.1m |
Earnings Waterfall
Pharming Group NV
|
Revenue
|
245.3m
USD
|
|
Cost of Revenue
|
-25.2m
USD
|
|
Gross Profit
|
220.1m
USD
|
|
Operating Expenses
|
-241.9m
USD
|
|
Operating Income
|
-21.8m
USD
|
|
Other Expenses
|
11.2m
USD
|
|
Net Income
|
-10.5m
USD
|
Free Cash Flow Analysis
Pharming Group NV
PHARM Profitability Score
Profitability Due Diligence
Pharming Group NV's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Pharming Group NV's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
PHARM Solvency Score
Solvency Due Diligence
Pharming Group NV's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Pharming Group NV's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHARM Price Targets Summary
Pharming Group NV
According to Wall Street analysts, the average 1-year price target for
PHARM
is 1.86 EUR
with a low forecast of 1.52 EUR and a high forecast of 2.21 EUR.
Shareholder Return
PHARM Price
Pharming Group NV
| Average Annual Return | 23.46% |
| Standard Deviation of Annual Returns | 66.14% |
| Max Drawdown | -59% |
| Market Capitalization | 570.4m EUR |
| Shares Outstanding | 671 073 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Pharming Group NV
Country
Industry
Market Cap
Dividend Yield
Description
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Contact
IPO
Employees
Officers
The intrinsic value of one
PHARM
stock under the Base Case scenario is
1.11
EUR.
Compared to the current market price of 0.85 EUR,
Pharming Group NV
is
Undervalued by 23%.
You don't have any saved screeners yet
